Latest news with #GlandPharma
&w=3840&q=100)
Business Standard
22-07-2025
- Business
- Business Standard
Glenmark, Laurus: 4 pharma stocks gain up to 79% in 5 months; time to exit?
The daily RSI, a key momentum indicator, shows that these 4 pharma stocks namely - Gland Pharma, Glenmark, Biocon and Laurus Labs are trading in the overbought territory; here's what to expect next. Rex Cano Mumbai Listen to This Article Shares of these 4 pharma companies namely - Glenmark Pharma, Gland Pharma, Biocon and Laurus Labs have zoomed up to 79 per cent since the start of the March 2025 - thus outperforming the benchmark Nifty and the sectoral index by a wide margin, in spite of the US pharma tariff-related uncertainties. In comparison, the NSE Nifty 50 index has gained 15.7 per cent, and the Nifty Pharma index has surged 15 per cent in the same period. Following the sharp rally in the last five months, technical charts now show that these 4 pharma stocks are trading
Time of India
21-07-2025
- Business
- Time of India
Brookfield, EQT Close In on Gland Pharma, but Rising Stock a Pain
Live Events Buyout groups Brookfield and EQT are in active discussions to buy Hyderabad-based Gland Pharma, a contract development and manufacturing organisation (CDMO) and injectables company, from China's Fosun Group in what could become one of the largest buyouts of the year in the segment, said people in the know. However, the galloping share price of Gland is a potential deal two private equity groups have been shortlisted after the initial round of bids earlier this such as CVC Capital Partners are also exploring a deal, said the people cited. Warburg Pincus is said to be weighing its options before taking a call, they Chinese parent has diversified investments that range from healthcare to football clubs, asset management, banks, estate, hospitality, fashion and industrials. The conglomerate has a presence across the pharma value chain from manufacturing to diagnostics and medical devices. Shanghai Fosun Pharmaceutical Co. had acquired an 86% stake in Gland Pharma in 2016 from KKR for a record deal value of $1.26 currently owns 51.8% of Gland, having pared its stake over the years. Market capitalisation has shot up to Rs 32,964.47 crore with the Gland Pharma stock appreciating 10% in the year to date in anticipation of a transaction. It closed Friday at Rs 2,000. In the past month alone, it has shot up 16%. The Fosun stake alone would require a payout of Rs 17,141.28 crore ($1.9 billion).Change of control will involve an open offer for an additional 26% of the company from minority shareholders, making it a much larger transaction. If the open offer is fully subscribed, it would translate to a Rs 25,711 crore ($3 billion) acquisition at current and Gland didn't respond to queries. Brookfield and EQT declined to investors are of the view the stock is overpriced and are interested only at a discount to the current level. 'There are macro headwinds because of industry glut and geopolitics,' said one of the people cited. 'Fosun has to decide if it is okay to sell at a significantly lower price.'This factor could be a deal breaker, analysts said. 'At this level, the process looks tough,' said another industry official. Fosun at various times in recent years, renewed its search for a strategic or financial deal for Gland Pharma. The company ran a full sale process last year but aborted it, only to revive plans earlier this summer, mandating Morgan Stanley and UBS. Mint was first to report that PE interest in Gland had revived in in 1978 by PVN Raju, Gland Pharma develops and manufactures generic injectables for use in nearly 90 countries on five continents, with a focus on the Indian and US markets. As with other Chinese companies, Fosun has faced regulatory issues in India due to the frosty relationship between the two countries. Even its entry into India faced significant delays with deal contours needing tweaks to comply with FDI norms. Some experts said Fosun sees the timing as ideal for an exit. But with no success for years, Fosun has been selling down its shares in the public markets through block deals. Last year, it sold about 6% for ₹1,750 crore. 'The incremental growth for the company's base business in the US is likely to come at the cost of margins,' said Shyam Srinivasan of Goldman management is expecting Cenexi Group — a French injectables and CDMO company Gland acquired in 2023 — to break even by the December quarter. Gland has a toehold in Europe through Cenexi, but rebooting the organisation and its product mix has been analysts said Gland has a sound track record and its future prospects may attract buyers.A veteran industry expert said Gland Pharma has a 'strong compliance history' and its manufacturing quality is impeccable. Plus, a surge in demand is seen for large injectable capacities across the world, making it a good fit. Another strong push for Gland Pharma is the explosive growth in glucagon-like peptide-1(GLP-1) drugs for weight loss and diabetes. Novo Nordisk's Wegovy (semaglutide) is set to go off patent early next year in India and Canada, leading to a burst of generic variants expected to enter the market. This is likely to offset the current overcapacity of injectable assets around the world. Trade tensions between the US and China are adding to the interest in Indian contract manufacturing players for steady supplies. 'Although we have not seen any meaningful switching from China yet, such opportunities cannot be ruled out in the future,' an industry executive is also preparing for a larger play in the biologics business, focusing on expanding its biosimilar and biologic CDMO segment.'The company's collaboration with DRL (Dr Reddy's) and discussions with Henlius (of China) are progressing well, with revenue generation from DRL business expected from FY26,' it said in the presentation.
&w=3840&q=100)
Business Standard
14-07-2025
- Business
- Business Standard
Gland Pharma shares rise on GMP nod for Telangana manufacturing unit
Shares of Gland Pharma Ltd. rose over 2 per cent in Monday's intraday session after the company received a Good Manufacturing Practices certification from the Danish Medicines Agency for its Pashamylaram facility in Telangana. The pharmaceutical company's stock rose as much as 2.12 per cent during the day to ₹1898.4 per share, the biggest intraday fall since July 1 this year. The stock pared gains to trade 1.27 per cent higher at ₹1,882.7 apiece, compared to a 0.30 per cent decline in Nifty 50 as of 9:40 AM. Shares of the company trade at the highest level since January 7 this year and currently trade at 4 times the average 30-day trading volume, according to Bloomberg. The counter has risen 5.5 per cent this year, compared to a 6 per cent advance in the benchmark Nifty 50. Gland Pharma has a total market capitalisation of ₹30,893.48 crore. Gland Pharma's Pashamylaram facility gets GMP certification The headcare major said that its Pashamylaram facility has received a 'Good Manufacturing Practices' (GMP) compliance certificate from the Danish Medicines Agency, according to an exchange filing. The certification was granted in connection with marketing authorisations that list manufacturers located outside the European Economic Area (EEA), it said. The approval covers aseptically prepared powder for injection, infusion, and inhalation, strengthening the company's regulatory credentials in European markets. Gland Pharma Q4 results Gland Pharma reported a 3 per cent year-on-year (YoY) decline in its consolidated net profit to ₹186.5 crore for the fourth quarter ended March 2025 (Q4FY25), compared to ₹192.4 crore in the same period last year. Revenue from operations fell 7 per cent YoY to ₹1,424.9 crore from ₹1,537.5 crore. The company's Ebitda stood at ₹347.5 crore, marginally down from ₹358.7 crore a year ago. About Gland Pharma Gland Pharma is a small-molecule generic injectables-focused company, with a global footprint across 60 countries, including the United States, Europe, Canada, Australia, India and other markets in the rest of the world. The firm has seven manufacturing facilities in India, comprising four facilities for finished formulations and three API facilities.
Business Standard
12-07-2025
- Business
- Business Standard
Gland Pharma gets GMP certificate for Telangana-based facility from Danish Medicines Agency
Gland Pharma said that its Pashamylaram facility has received certificate of good manufacturing practices (GMP) compliance from Danish Medicines Agency. Pashamylaram is a village located in Patancheru mandal of Medak district in Telangana, India. This certification specifically covers the facility's production of aseptically prepared powder for injection, infusion, and inhalation. This GMP certificate is crucial for Gland Pharma as it pertains to marketing authorizations that list manufacturers located outside of the European Economic Area (EEA), allowing their products to be marketed within Denmark and potentially other EEA countries. Gland Pharma is one of the largest and fastest-growing injectable-focused companies, with a global footprint across 60 countries, including the United States, Europe, Canada, Australia, India, and other markets. It has a wide range of injectables, including vials, ampoules, pre-filled syringes, lyophilized vials, dry powders, infusions, oncology, and ophthalmic solutions. The company also pioneered heparin technology in India. The company's consolidated net profit declined 3.06% to Rs 186.54 crore as net sales fell by 7.32% to Rs 1424.91 crore in Q4 FY25 as compared with Q4 FY24. The scrip had gained 0.89% to end at Rs 1859.05 on the BSE on Friday.
Business Standard
11-07-2025
- Business
- Business Standard
Gland Pharma's Pashamylaram facility receives GMP certification from Danish Medicines Agency
For aseptically prepared Powder for injection, infusion and inhalation Gland Pharma announced that the Pashamylaram facility of the Company has received certificate of Good Manufacturing Practices (GMP) Compliance from Danish Medicines Agency in connection with Marketing authorizations listing manufacturers located outside of the European Economic Area, for aseptically prepared Powder for injection, infusion and inhalation.
